



**To:** All PCPs, Specialists & IPAs  
**From:** IEHP – Provider Relations  
**Date:** June 29, 2022  
**Subject:** **ALERT: No Prior Authorization for Biomarker Testing for Stage 3 and 4 Metastatic Cancers**

---

---

Inland Empire Health Plan (IEHP) would like to notify our providers and IPA partners that effective July 1, 2022; **NO prior authorization (PA) is required for either of the following services:**

- Biomarker testing for Members with advanced or metastatic stage 3 and 4 cancers.
- Biomarker testing for cancer progression or recurrence in Members with advanced or metastatic stage 3 or 4 cancers.

This change is in accordance with the requirements of section 1367.665 of the California Health and Safety Code, California Senate Bill 535, the Department of Managed Health Care (DMHC) All Plan Letter (APL) 21-025 and the Department of Health Care Services (DHCS) APL 22-010. For more information on these APLs, visit:

<https://www.dmhc.ca.gov/licensingreporting/healthplanlicensing/allplanletters.aspx>  
<https://www.dhcs.ca.gov/formsandpubs/Pages/AllPlanLetters.aspx>

Thank you for helping us provide optimal care for our most vulnerable members.

As a reminder, all communications sent by IEHP can also be found on the Provider portal:  
[www.iehp.org](http://www.iehp.org) > For Providers > Plan Updates > Correspondence

If you have any questions, please do not hesitate to contact the IEHP Provider Relations Team at (909) 890-2054, (866) 223-4347 or email [ProviderServices@iehp.org](mailto:ProviderServices@iehp.org)